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REVIEW
Abstract: Anxiety symptoms are frequently present in patients with late-life depression. The
designation “anxious depression” has been used to describe major depressive disorder (MDD)
accompanied by clinically significant but subsyndromal anxiety symptoms. MDD may also
present comorbid with diagnosable anxiety disorders, although this presentation is less common
in late life. Diagnosis of anxious depression in the elderly is complicated by several factors
(eg, their tendency to experience and report psychiatric symptoms as somatic illness) and is
associated with a more severe clinical presentation, increased risk for suicidal ideation,
increased disability, and poorer prognosis. Standard pharmacotherapy for depression may be
sufficient but for many patients must be modified or augmented. Psychosocial interventions
may also be an important component in the treatment of these patients, although no specific
psychosocial treatments have been developed for late-life anxious depression.
Keywords: late-life, anxious depression, geriatric, anxiety, depression
Introduction
The importance of recognition and treatment of late-life psychiatric disorders has
been highlighted recently (Katz 1998; Jeste et al 1999). Depression and anxiety are
two of the most common psychiatric problems among older adults and frequently
co-occur (Lenze, Mulsant, et al 2001). Geriatric patients with depression and anxiety
also present special challenges for physicians (Small 1997; Katz 1998). For example,
increased medical comorbidity and changes in cognitive status may confound
diagnosis. Other cohort characteristics (eg, fears of stigma regarding mental illness;
tendency to attribute psychiatric symptoms to medical causes) may lead to
underreporting of psychiatric symptoms. In addition, most older adults seek
psychiatric care from primary care physicians rather than from mental health
specialists (Wetherell et al 2004). System challenges in the primary care setting (eg,
short appointment times) present additional barriers to assessment of late-life
depression and anxiety (Katz 1998; Watts et al 2002).
Recognition of late-life depression and anxiety is critical given the associated
personal and healthcare system burden, including higher rates of service utilization,
increased risk for medical illness and disability, and higher mortality rates (Lecrubier
2001; Hybels and Blazer 2003). The co-occurrence of depression and anxiety is also
associated with more severe emotional distress, increased risk for suicidal ideation,
and poorer treatment response (Flint and Rifat 1997a; Lenze et al 2000). Despite the
clear public health significance of late-life depression and anxiety, these problems
remain underrecognized and inadequately treated (Small 1997; Young et al 2001).
“Anxious depression” is not a formally recognized psychiatric disorder, but the
term is commonly used to describe a clinical picture in which symptoms of both
depression and anxiety are prominent. Several clinical presentations are described in
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the literature (Silverstone and von Studnitz 2003).
Depression and anxiety may co-occur at the caseness level,
when the patient meets full diagnostic criteria for both a
depressive and an anxiety disorder. Anxious depression may
also describe a patient diagnosed with major depressive
disorder (MDD) who presents with clinically significant but
subsyndromal anxiety symptoms. Others use this term to
refer to the clinical presentation similar to mixed anxiety
depressive disorder (MADD), which is characterized by the
coexistence of clinically significant but subsyndromal
depression and anxiety symptoms with neither diagnostic
threshold met (APA 1994). Consistent with a recent review
by Lenze, Mulsant, and colleagues (2001), we use the term
comorbid depression and anxiety to refer to diagnostic
comorbidity and anxious depression to refer to diagnosed
MDD coexistent with subsyndromal anxiety symptoms.
When appropriate, we specify that data refer to coexistent
depressive and anxiety symptoms or MADD, although this
article does not focus on this construct.
In this review we outline the conceptualization,
epidemiology, risk factors, and clinical correlates of late-
life anxious depression. We also discuss the special
challenges of differential diagnosis and review the literature
on pharmacological and psychosocial interventions. Given
that so many questions remain unanswered, we conclude
by discussing future directions for research in this area.
Conceptualizations of anxious
depression
A diagnosis of MDD is a component of some conceptual-
izations of anxious depression. A formal diagnosis of MDD
requires the presence of at least five specified symptoms,
one of which must be sad mood or loss of interest in
activities. The remaining four (or three if both of the above
are present) may be any of the following: sleep
dysregulation, feelings of worthlessness, appetite changes,
fatigue, suicidal ideation, or psychomotor agitation or
retardation. Symptoms must be present most of the day
nearly every day for 2 weeks or more (APA 2000). As
mentioned previously, MDD is present in comorbid anxiety
and depression (when an individual is diagnosed with a
comorbid anxiety disorder) and in anxious depression (when
an individual presents with coexistent clinically significant
but subsyndromal anxiety symptoms). MADD, however,
would not include a diagnosis of MDD, given that both
depression and anxiety symptoms are subsyndromal.
Anxiety disorders are characterized by an exaggerated
fear response and attempts to reduce, escape, or avoid threat.
The fear response may be exaggerated when individuals
misattribute threat or have an extreme emotional reaction
to nonthreatening or minimally risky situations, thoughts,
emotions, or somatic symptoms. Avoidance can take many
forms, including total refusal to face a given situation and
engaging in “anxiety behaviors” that reduce anxiety (ie,
behaviors that allow the individual to temporarily avoid
anxiety). Common anxiety behaviors among older adults
are reassurance seeking (eg, repeated calls to a physician
regarding a test result) or checking behaviors (eg, excessive
checking of blood pressure, repeated phone calls to family
members to confirm their wellbeing).
In addition to sharing these general features, each anxiety
disorder is defined by specified symptom clusters (APA
2000). Generalized anxiety disorder (GAD) is the most
common late-life anxiety disorder (Beekman et al 1998).
GAD is characterized by excessive and uncontrollable
worry, accompanied by three or more hyperarousal
symptoms (ie, restlessness, fatigue, concentration problems,
sleep dysregulation, muscle tension, irritability) more days
than not, for at least 6 months. Worry associated with GAD
is “diffuse” and related to two or more topics (eg, health,
family, finances). Phobias are also common in late life and
are characterized by excessive fear and, typically, avoidance
of discrete situations (eg, fear of driving, fear of social
situations). A unique type of phobia, called agoraphobia, is
characterized by fear and avoidance of situations in which
individuals believe they may experience physical symptoms
(eg, a panic attack) and escape will be difficult or assistance
not readily available (eg, in crowded areas). Agoraphobia
may present in the elderly following a significant medical
event (eg, heart attack) or may present with those who have
a history of panic disorder. Other anxiety disorders are rare
among older adults in community settings. For example,
panic disorder is rare in community settings, but is more
common among older adults with MDD (Regier et al 1988;
Lenze et al 2000); obsessive-compulsive disorder is rare
among elderly with or without MDD; and one study also
found low prevalence of post-traumatic stress disorder
among those with MDD (Flint 1994; Lenze et al 2000).
In late life, MDD co-occurring with prominent but
subsyndromal anxiety symptoms may be even more
pertinent than comorbid depression and anxiety. Table 1
presents common anxiety symptoms that may co-occur with
MDD, some of which are among the diagnostic criteria for
anxiety disorders (APA 2000) and others are from the
authors’ clinical experience. Symptoms of GAD are most
common among older adults with MDD (Lenze et al 2000).Clinical Interventions in Aging 2006:1(1) 43
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More research is needed to identify the symptom profile of
late-life anxious depression; however, several issues
complicate the refinement of this construct. First, there is
an overlap in the symptoms of anxiety and depression. For
example, sleep disturbance, concentration problems, and
fatigue are criteria for both MDD and GAD. In addition, it
is more difficult to differentiate anxiety and depressive
symptoms in elderly patients (Parmelee et al 1993).
Patients may also present with subsyndromal symptoms
of both depression and anxiety. The clinical relevance of
subsyndromal psychiatric symptoms is receiving increased
attention across the lifespan. For example, a large field trial
to define the features of subsyndromal depression and
anxiety among a sample of mixed-age primary care patients
identified the following symptoms as most characteristic:
concentration or memory problems, hypervigilance,
hopelessness, feelings of worthlessness, fatigue, sleep
disturbance, anticipating the worst, worry, irritability, and
being easily moved to tears (Zinbarg et al 1994).
Subsequently, MADD was defined as a disorder for further
study (APA 1994). MADD is currently defined as persistent
or recurrent dysphoric mood occurring along with at least
four additional symptoms (listed above) for 1 month or more.
The current MADD criteria are somewhat restrictive,
perhaps overly so for geriatric patients, given that the
diagnosis cannot be made when full criteria for mood or
anxiety disorders have ever been met.
Epidemiology
The prevalence of MDD among adults 65 years or older
living in the community is less than 1% (Weissman et al
1988). However, MDD is the most common psychiatric
diagnosis for older nondemented psychiatric patients (Cooke
et al 2004). In addition, the rate of MDD among older adults
has been reported as 9% in older primary care patients
(Areán and Alvidrez 2001), 11.5% in hospitalized medical
patients (Koenig et al 1988), and 13.5% of older adults
receiving home healthcare services (Bruce et al 2002).
Comorbidity rates for MDD and anxiety disorders are high.
In community-based studies, 47.5% of depressed elderly
also meet diagnostic criteria for an anxiety disorder
(Beekman et al 2000). Among older primary care patients
with depression, 61.4% also have an anxiety disorder
(Turrina et al 1994). Although some studies have found low
rates (5%) of anxiety disorder diagnoses among older
depressed psychiatric patients (Mulsant et al 1996), those
utilizing prospective designs with enhanced training of
personnel reported a higher prevalence (23.1%) (Lenze et
al 2000). Anxious depression may be even more common
than is a comorbid diagnosis of both MDD and an anxiety
disorder. Of older primary care patients with depression,
74% reported significant anxiety symptoms (Watts et al
2002), and 64.9% of elderly nursing home residents with
MDD have significant anxiety symptoms (Parmelee et al
1993). In addition, 27.5%–30.9% of older psychiatric
patients diagnosed with MDD report clinically significant
symptoms of GAD (Lenze et al 2000; Steffens and McQuoid
2005). GAD symptoms are the most common anxiety
symptoms among older adults with and without depression
(Heun et al 2000; Lenze et al 2003).
Risk factors
Demographic characteristics associated with late-life
depression or anxiety are female gender, unmarried status
(especially for men), and lower income (Blazer et al 1991;
Heun et al 2000). Of these characteristics, female gender is
the most consistent demographic risk factor reported. Other
common risk factors are family or personal history of
depression or anxiety. Of note, while older age per se is not
associated with increased risk, the physical and cognitive
decline and associated functional disability that often occur
with aging have been reported as risk factors for late-life
depression or anxiety (eg, Lenze, Martire, et al 2001; Hybels
and Blazer 2003). Cardiovascular disease must be
considered because it may predispose to “vascular
depression”, characterized by late onset, psychomotor
retardation, poor insight, and cognitive impairment
(Alexopoulos et al 1997). Late-onset depression may also
be associated with triggering psychosocial stressors
(Brilman and Ormel 2001), the most common of which is
Table 1 Common late-life anxiety symptoms
Unrealistic fears
Excessive and uncontrollable worries 
Behavioral agitation
Irritability
Muscle tension
Sleep onset insomnia
Fatigue
Concentration problems
Heart palpitations
Shortness of breath
Tightness in chest
Stomach distress
Trembling or shaking
Headache
Excessive reassurance seeking
Excessive checking
Avoidance of feared situationsClinical Interventions in Aging 2006:1(1) 44
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bereavement (eg, death of a spouse). Older adults high in
the personality trait of “neuroticism” and who experience
chronic life stress are particularly at risk for developing
depression following an acute stressful life event (Ormel et
al 2001).
Several studies have investigated risk factors specific to
late-life comorbid depression and anxiety or anxious
depression. In a large community-based sample, comorbid
depression and anxiety was associated with being unmarried,
having functional limitations, an external locus of control
(a personality trait characterized by believing life ex-
periences are caused by circumstances outside one’s
control), family history, life events, and death of partner
(Beekman et al 2000). Death of partner was the strongest
predictor of comorbid depression and anxiety. In another
large community sample, female gender, younger age,
service utilization, personal history, disability, and cognitive
decline were risk factors for comorbid depression and
anxiety (Schoevers et al 2003). Female gender was the
strongest predictor, and younger age and service utilization
were unique predictors of comorbid depression and anxiety
(relative to diagnosis of only one disorder). These findings,
however, contrast with research demonstrating that
disability, psychosocial stressors, medical illness, and
cognitive status did not add to depression severity in the
prediction of severity of anxiety symptoms among elderly
psychiatric patients with MDD (Flint and Rifat 2002).
Impact on health, functioning, and
quality of life
The negative effect of late-life depression and anxiety
disorders on health, functioning, and quality of life is well
documented. Depression and anxiety are risk factors for
medical illness and adversely affect recovery from medical
illness (Doraiswamy 2001). For example, depression and
anxiety increase medical complications, recovery times, and
mortality in patients with cardiovascular disease (eg, Moser
and Dracup 1996; Schulz et al 2000). Older adults with
depression or anxiety also are high users of healthcare
services (Koenig and Kuchibhatla 1999; Stanley et al 2001).
Risks of functional disability, cognitive decline, and nursing
home placement also increase with depression or anxiety
(Lenze, Martire, et al 2001; Gibbons et al 2002; Sinoff and
Werner 2003). Perceived health quality and quality of life
are negatively affected by late-life depression or anxiety
(Maddux et al 2003). Notably, the effects of depression and
anxiety may be additive. Older psychiatric patients with
anxious depression report more severe psychiatric
symptoms, poorer social functioning, and more severe
somatic complaints than those with depression alone (Lenze
et al 2000; Schoevers et al 2003). There is also an increased
risk for suicidal symptoms among older adults with anxious
depression (Lenze et al 2000; Bartels et al 2002).
Impact on prognosis
Pharmacological studies in late-life MDD have shown
poorer response to psychiatric treatment for those with
anxious depression. For example, in a study of 101 older
depressed psychiatric outpatients, those with anxious
depression were more likely to discontinue treatment and
to have an attenuated response to nortriptyline (Flint and
Rifat 1997a). In a 2-year follow-up study, Flint and Rifat
(1997b) reported that residual anxiety symptoms following
successful treatment of MDD predicted a shorter time to
relapse of depression. Evaluation of treatment response for
depressed elderly receiving nortriptyline and interpersonal
therapy indicates that those with comorbid anxiety disorders
or anxious depression experience delayed or attenuated
treatment response and an increased likelihood of needing
pharmacological augmentation (Mulsant et al 1996; Dew
et al 1997). A recent evaluation from Steffens and McQuoid
(2005) demonstrated that the presence of GAD symptoms
was associated with longer time to remission of depressive
symptoms among elderly inpatients and outpatients with
MDD. These patients were treated with pharmaco-
therapy (based on an algorithm) with augmentation of
electroconvulsive therapy and/or cognitive-behavioral
psychotherapy as clinically indicated. In an ongoing trial
of citalopram (with psychotherapy augmentation if
necessary) for older depressed primary care patients, those
with anxious depression demonstrated a lower response rate
and longer time to response despite having a higher rate of
treatment augmentation (Lenze et al 2002).
In a notable exception to the accumulating evidence for
poorer response associated with anxious depression, Lenze
and colleagues (2003) have published two studies with a
total of 241 older psychiatric outpatients with MDD. One
was a randomized, double-blind comparison trial of
nortriptyline and paroxetine; the other was an open trial of
treatment with paroxetine and interpersonal therapy. There
were no differences between the anxious and nonanxious
depressed patients on rate of response, time to response, or
attrition. In fact, somatic complaints were reduced more
quickly and significantly in the anxious depression group.
Results were replicated when comparing groups based on
the presence of comorbid anxiety disorders. It was suggestedClinical Interventions in Aging 2006:1(1) 45
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that outcome for treatment of anxious depression in this
study may have benefited from greater clinical efforts than
in previous studies to reduce attrition (eg, providing
reassurance, including phone contact between scheduled
appointments). Thus, adaptations in clinical management,
including close monitoring of side effects and somatic
complaints early in treatment and referrals to specialty
mental health centers, may be necessary to improve
treatment outcomes, perhaps especially in patients with
anxious depression (Lenze et al 2002).
Differential diagnosis
Medical conditions that can mimic or present with
disturbances in mood and symptoms of anxiety are
extensively discussed in many standard textbooks (eg, Hales
and Yudofsky 2002). The differential diagnosis includes
thyroid and parathyroid disease, primary cardiac pulmonary
disease (mitral valve prolapse, arrhythmias, chronic
obstructive pulmonary disease, coronary insufficiency),
substance withdrawal, hypoglycemia, various malignancies
and autoimmune conditions, Parkinson’s disease, dementia,
multiple sclerosis, and metabolic and gastrointestinal
disorders. There are additional considerations in the
evaluation of elderly patients with symptoms of anxious
depression. Many of the medical conditions that must be
considered in a differential diagnosis of MDD are more
common with increasing age (eg, Parkinson’s disease,
stroke, and dementia) and thus are of relatively greater
importance in evaluating the elderly patient. When MDD is
accompanied by prominent symptoms of anxiety, the
differential is even more extensive (eg, cardiac arrhythmias,
mitral valve prolapse, drug and alcohol withdrawal).
Differential diagnosis in the elderly patient is
complicated by several factors. For example, mood and
anxiety symptoms are common in patients with an
established medical diagnosis, and the elderly are more
likely than younger patients to have a medical illness.
Somatic symptoms, common in both depression and anxiety,
can mimic a number of medical disorders, including
cardiovascular, neurological, and gastrointestinal disorders.
In addition, the psychiatric illness may be unrecognized and
untreated, especially in elderly patients whose physical
complaints may be attributed to a tendency to ruminate or
to worry excessively, or be incorrectly attributed to the
consequences of aging. The life circumstances of many
elderly individuals can also complicate the accurate and
timely diagnosis of a mood or anxiety disorder, making it
more difficult to determine if the Diagnostic and statistical
manual of mental disorders criterion of “excessive” worry
or anxiety is met. For example, concerns related to realistic
financial or health stressors can be viewed as a manifestation
of depression or anxiety, resulting in an unnecessary and
ineffective treatment intervention.
As noted above, a number of psychiatric disorders must
be considered when evaluating patients with anxiety and
disturbances in mood, although some would rarely present
for the first time in late life (eg, schizophrenia). Of particular
concern in older individuals is the recognition in depressed
patients of cognitive impairment and of psychotic symptoms.
In the former, a diagnosis of “anxious depression” may be
misapplied if agitation and attempts to accommodate to
declining cognitive capacity are attributed to “worry” or are
considered the “pseudodementia” of depression. In the latter
scenario, the depressed patient with delusions may be
misdiagnosed as merely agitated, or fearfulness in the
anxious patient may be incorrectly viewed as evidence of
psychosis. As mentioned above, the effects of alcohol, illicit
drugs, and prescribed medications must be considered when
evaluating both physical complaints and psychiatric signs
and symptoms (Kaempf et al 1999; Clark et al 2004). Acute
and chronic effects of these agents are of concern as well as
withdrawal states (eg, alcohol, benzodiazepines) (Oslin
2004). Patients of any age may intentionally misuse
prescription medications, but this issue has recently been
found to be underrecognized in the elderly (Petrovic et al
2002; Weintraub et al 2002; Clark et al 2004). Older patients
are also vulnerable to adverse consequences related to age-
related slower drug metabolism, increased sensitivity to side
effects (eg, sedation), and drug–drug interactions (given that
older patients are more commonly on multiple medications).
Pharmacological interventions
As discussed above, anxious depression is not a formally
recognized diagnosis, and there are no pharmacotherapy
guidelines specific to this condition. Furthermore, most
randomized, controlled trials exclude patients with medical
comorbidities and other features commonly seen in the
elderly, resulting in a very limited “evidence base” about
the treatment of these patients. Even for patients well
represented in randomized, controlled trials there remains
a trial and error component to therapeutic decisions, a
problem dramatically illustrated in the treatment of late-
life anxious depression.
Most medications used in the treatment of MDD and
anxiety in the general adult population can be considered
for these conditions in the elderly. Most of the drugsClinical Interventions in Aging 2006:1(1) 46
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originally developed and marketed as antidepressants have
also been found to be effective in one or more of the anxiety
disorders, although all do not have US FDA-approved
indications for the latter. The most prominent example is
the selective serotonin reuptake inhibitors (SSRIs), which
have largely replaced tricyclic antidepressants (TCAs) and
the monoamine oxidase inhibitors (MAOIs) in clinical
practice. The SSRIs are easier to use and, perhaps especially
for geriatric patients, may have a more favorable side effect
profile. Therefore, it is reasonable to consider SSRIs the
first line of treatment in elderly patients with anxious
depression. Although there is insufficient evidence to
conclude that there are differences in efficacy among the
various SSRIs, side effects such as sedation may determine
drug preference. There are also differences in the FDA-
approved indications for these drugs. Table 2 summarizes
the FDA-approved medications (SSRIs and related
medications) for treatment of MDD and anxiety disorders
in adults. Several FDA-approved antidepressants have not
been adequately studied in patients with anxiety disorders,
and there are fewer published data supporting their use in
anxious depression (eg, mirtazapine, duloxetine, bupropion).
Nonetheless, any effective antidepressant may also be
effective for anxious depression, especially since symptoms
of anxiety may resolve as depression improves.
When monotherapy with antidepressants at conventional
dosages is not effective, a next step can be a dosage increase,
a change to a different class of antidepressants, or an
augmentation strategy. With regard to dosage, it is important
to remember that the risk of side effects increases with
dosage and that tolerability is a relatively greater concern
in the elderly – thus the axiom “start low and go slow”.
Equally important, however, is the need to extend treatment
trials to the degree tolerated before concluding that a given
agent is not effective. To address this principle, Lenze,
Mulsant, et al (2001) have recently recommended an
additional adage: “aim high (dosage) and treat long”. When
antidepressant monotherapy is not adequate, augmentation
strategies include venlafaxine, mirtazapine, a TCA (or other
antidepressant), and gabapentin and buspirone. Not well
studied is the response of different components of the
anxiety symptom cluster (eg, mental/emotional complaints
versus physical symptoms) to specific drugs. Future
research may identify, for example, more specific indications
for TCAs in some forms of anxious depression, just as
β-blockers, while not generally useful for anxiety, may be
helpful on an as-needed basis in patients with anxiety limited
to specific situations (eg, public speaking). Note that
although the required dosage of a β-blocker is usually low
(eg, propranolol 50 mg), these agents may not be tolerated
in patients with comorbid medical conditions such as
asthma, congestive heart failure, or sinus bradycardia, and
the prominent anticholinergic effects of TCAs may limit
this treatment option.
Adjunctive pharmacotherapy with benzodiazepines in
geriatric patients deserves special mention. Use of
benzodiazepines as a treatment for anxiety disorders in
general and in geriatric patients in particular has been widely
debated (Shorr and Robin 1994). A full discussion of this
issue is beyond the scope of this paper, but in support of
their use, especially early in the treatment of patients with
marked symptoms of anxiety, is rapidity of onset. Such a
strategy may also be useful in patients who experience
agitation on initiation of therapy with an SSRI.
Benzodiazepines may not be well tolerated by some geriatric
patients, and the risk-benefit ratio must be assessed on a
patient-by-patient basis. Risks to consider in this analysis
are cognitive impairment, disrupted coordination (ie, risk
of falls), and potential withdrawal effects if the medication
is not tapered appropriately after long-term use (Shorr and
Robin 1994; Hanlon et al 1998). In addition, the benzo-
diazepine of choice may be different for elderly patients;
long half-life agents such as clonazepam may generally be
preferable to the short half-life options in treating anxiety,
but in the elderly there is much less risk of drug accumulation
with the latter (eg, lorazepam).
Anxious depression in the elderly is a treatment
challenge, one that requires designing a patient-specific
approach (eg, recognition of the patient’s age-related
characteristics, of variables that can influence medication
choice and dosing, and of suitability for psychotherapy and
Table 2 FDA-approved indications for selected antidepressants
Social
Panic anxiety
Antidepressant MDD GAD OCD PTSD disorder disorder
Citalopram ²
Escitalopram ²²
Fluoxetine ²² ²
Fluvoxamine ²
Paroxetine ²² ² ² ² ²
Sertraline ²² ² ² ²
Venlafaxine ²² ²
Bupropion ²
Mirtazapine ²
Duloxetine ²
Abbreviations: MDD, major depressive disorder; GAD, generalized anxiety
disorder; OCD, obsessive-compulsive disorder; PTSD, post-traumatic stress
disorder.Clinical Interventions in Aging 2006:1(1) 47
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psychosocial interventions). Knowledge of the wide variety
of presentations is critical, as is awareness of the different
patterns of treatment response. The clinician must determine
the specific cluster of symptoms that is the target for
pharmacotherapy. In formulating treatment it may be more
useful to think of signs and symptoms not as now classified
in the various DSM categories but as disturbances that may
present in different combinations and permutations. At
present it is not known if particular clusters of symptoms
predict response to specific therapies. Anxiety, for example,
may or may not resolve as the depression improves, and
some symptoms may persist even in patients “successfully”
treated for MDD.
Psychosocial interventions
There are no psychosocial interventions specific to treatment
of late-life anxious depression. However, a consensus
statement has identified psychotherapy, either alone or in
combination with pharmacotherapy, as an efficacious
treatment for late-life depression (Lebowitz et al 1997). Of
these interventions, cognitive-behavioral therapy (CBT) and
interpersonal therapy (IPT) have received the strongest
empirical support. CBT is a short-term, problem-focused
treatment, which aims to teach and/or strengthen coping
skills (eg, evaluating and changing negative thoughts,
problem solving). In randomized, controlled trials, CBT has
demonstrated superior effects over waiting list or usual care
for late-life MDD (Areán and Cook 2002). In addition, one
study found CBT alone or in combination with desipramine
superior to desipramine treatment alone for late-life MDD
(Thompson et al 2001). IPT engages patients in interpersonal
problem solving and in processing emotional distress. Most
IPT research has evaluated the efficacy of this treatment in
combination with pharmacotherapy or pill placebo and
found IPT combination therapy superior to placebo or
pharmacotherapy alone for late-life MDD (Areán and Cook
2002). Finally, collaborative care models have demonstrated
effectiveness for treatment of late-life depression in medical
settings (Unützer et al 2002).
Far less research has been conducted on the psychosocial
treatment of late-life anxiety, and most of this has focused
on treatment of GAD. Initial reports indicate that CBT is a
promising psychosocial intervention for late-life GAD. In
randomized, controlled trials, group CBT has demonstrated
superiority over weekly therapist monitoring of symptoms
or a waiting list, but was not generally superior to other
group supportive therapy or discussion group (Stanley et al
1996; Stanley, Beck, et al 2003; Wetherell et al 2003).
Similar positive effects have been found for individual CBT
compared with usual care for primary care patients with
GAD (Stanley, Hopko, et al 2003). Preliminary data suggest
that cognitive aids may enhance the effect of CBT for late-
life GAD (Mohlman et al 2003). Other research has found
CBT superior to a waiting period, with some superiority for
CBT over supportive therapy for treatment of older adults
with a variety of anxiety disorders (Barrowclough et al
2001). CBT has also been established as an efficacious
treatment for other anxiety disorders among young and
middle-aged adults (Nathan and Gorman 1998), with a few
case studies supporting its use in late life (eg, Carmin et al
2002). However, more research is needed to increase the
evidence base for psychosocial treatment of late-life anxiety
disorders.
No specific psychosocial intervention has been
developed to address late-life anxious depression. Recent
geriatric programs, however, are recognizing subsyndromal
symptoms as targets for psychosocial intervention and are
combining interventions for anxiety and depression into
“modualized” CBT treatment programs for older adults
(Wetherell et al 2005; Stanley et al in press). Thus, therapists
are able to select from a variety of interventions to
individualize treatment. Some components of CBT are
common to both older and younger adult interventions for
anxiety or depression (eg, relaxation, cognitive therapy,
behavioral activation, reducing avoidance). Others have been
integrated to address issues more relevant to older adults
(eg, pain management, life review). Modualized inter-
ventions are innovative and provide a more comprehensive
and flexible treatment. Similar approaches are likely to
enhance treatment of late-life anxious depression, although
additional research in this area is needed.
Conclusions and directions for
future research
Late-life anxious depression has clinical and public health
significance, as it is a common clinical presentation in a
variety of geriatric care settings and is associated with
increased health risks. There is increased emotional distress,
suicidality, and functional impairment and decreased quality
of life and health status in patients with late-life anxious
depression. Thus, there is a need for improved recognition
and treatment of older adults with anxious depression.
Further research is critical. One pressing need is to refine
the taxonomy of late-life anxious depression. As noted in
this review, several models of anxious depression have been
advanced. Whether an individual meets criteria for thresholdClinical Interventions in Aging 2006:1(1) 48
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MDD and/or anxiety disorder diagnosis is prominent in
differentiating these conceptualizations. However, since
older adults may be more likely to experience and/or report
clinically significant but subsyndromal symptoms, the
requirement that full criteria for comorbid MDD and anxiety
are met may be too stringent for late-life anxious depression.
MADD, defined as a mixture of subsyndromal depressive
and anxiety symptoms and listed as a disorder for further
study (APA 1994), may be a useful model for research on
late-life anxious depression. However, even this approach
may be too limiting, given that MADD precludes having
ever met criteria for a mood or anxiety disorder.
In future research, the term “anxious depression” would
be most useful if limited to patients with MDD and
prominent symptoms of anxiety, and a unique term should
be given to patients with coexisting depressive and anxiety
disorders. The criteria for “prominent” anxiety symptoms
have been defined in different ways across studies and
should be standardized. Researchers have often used cut-
off scores on anxiety symptom measures to differentiate,
among patients with MDD, those with and without anxious
depression. A first step to clarifying the nature of this
construct may be to derive empirically the criteria for the
anxiety symptoms characteristic of late-life anxious
depression. This research must also take into account the
level of specificity of anxiety symptoms (eg, identifying
symptoms that do not overlap with MDD criteria). These
data will facilitate putting forth a universal definition of late-
life anxious depression for future research. A similar but
broader research aim is to identify subtypes of late-life
depression and to define the characteristics of these subtypes
(eg, anxious depression may be one subtype of late-life
MDD). Finally, risk factors, triggering events, course,
psychosocial correlates, and treatment response are all
important phenomenological elements to be outlined for
MDD subtypes, including anxious depression.
Refining the definition of late-life anxious depression
will improve recognition of this condition and allow for
development and validation of assessment measures. There
are many widely used measures of depression and anxiety
(Nezu et al 2000; Antony et al 2001), only a few of which
have been developed and validated specifically for older
adults (eg, Yesavage and Brink 1983; Wisocki 1988) and
none of which specifically assesses for anxious depression
among older adults. Measures with simple response choices
and uncomplicated language are important in assessment
of older adults, and brief screening measures are needed in
primary care settings.
It will also be important to consider late-life anxious
depression in the context of older adulthood as a develop-
mental phase. Symptoms of depression and anxiety
commonly co-occur across the lifespan (eg, Brown et al
2001). Patients with life-long depression and/or anxiety
diagnoses age, but the research focus for anxious depression
should be on previously unrecognized symptoms or issues
newly presenting in geriatric patients. For example, aging
is associated with an increase in realistic risks (eg, declining
health and cognitive status), and this context must to taken
into account when assessing and treating geriatric patients.
Losses associated with retirement, decreased independence,
and death of friends and loved ones are important factors
when working with elderly. These developmental issues
highlight the potential role of psychosocial treatments for
those with late-life anxious depression. Strengthening
resilience, acceptance, and coping within the context of
difficult life changes will be an important component for
psychosocial treatments for late-life anxious depression.
While consensus guidelines for late-life anxious
depression are lacking, researchers are beginning to outline
treatment decision-making based on both empirical data and
clinical experience (eg, Lenze et al 2002). At present there
is no “one size fits all” approach to treatment of late-life
anxious depression, and each individual must be treated on
the basis of patient characteristics, such as symptom profile,
medical comorbidity, and psychosocial stressors. Both
pharmacological and psychosocial treatment options should
be considered. Additional research is needed to develop
psychosocial interventions for patients with late-life anxious
depression. In addition, outcome studies will need to
evaluate the efficacy and effectiveness of these interventions
in various populations. Ultimately, identification of
symptom profiles that are predictors of response to different
treatments will inform patient-to-treatment matching
algorithms.
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